Thanks Mason.
Today’s Ann was related to Breast cancer and seems Bisantrene had excellent results though the FTO expression was lower compared to say ovarian cancer where FTO expression is higher (per below diagram).
My questions are:
1. Based on what you have mentioned is FTO may be the cause for various cancers and we can treat the cause (FTO) and we can also treat the symptoms (Breast/ ovarian cancers) vs other SOC drugs which only treat the symptoms?
2. After the FTO results are announced (at some point) would RACE still need to do trials for each condition or would we then be able to extrapolate the results from FTO trials and breast/ ovarian cancer results?
Thanks.
Ann: Compelling Preclinical Breast Cancer Results, page-104
-
- There are more pages in this discussion • 150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $647.3K | 344.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3300 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |